SignalXSignalX

TNDM TANDEM DIABETES CARE INC

FY2025 10-K
Filed: Feb 19, 2026
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR
TANDEM DIABETES CARE INC Overview

TANDEM DIABETES CARE INC (TNDM) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business model: Design, development, and commercialization of advanced insulin delivery and diabetes technology with AID systems featuring Control-IQ+ hybrid closed-loop technology
  • • New product emphasis: Expanded commercial availability of Tandem Mobi with Android control (2025) and Control-IQ+ algorithm cleared for type 2 diabetes (18+ years) in 2025
+3 more insights

Management Discussion & Analysis

  • • Revenue $1.015B in 2025, up 8% YoY from $940.2M in 2024; U.S. sales $706.9M (+5%), international $307.8M (+15%)
  • • Gross margin 54% in 2025 vs 52% in 2024; operating loss $(187.3M) vs $(99.1M) reflecting higher operating expenses ($733.3M vs $588.7M)
+3 more insights

Risk Factors

  • • Cybersecurity risk managed by dedicated Incident Management Team led by VP, Cybersecurity with 20+ years industry experience
  • • Escalation protocols include disclosure committee and Cybersecurity and Data Privacy Oversight Committee to address significant incidents
+3 more insights

Get deeper insights on TANDEM DIABETES CARE INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available